The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.
Aged
Antineoplastic Agents
/ therapeutic use
Colorectal Neoplasms
/ drug therapy
Databases, Factual
/ statistics & numerical data
Female
Gastrointestinal Neoplasms
/ drug therapy
Gastrointestinal Stromal Tumors
/ drug therapy
Humans
Imatinib Mesylate
/ therapeutic use
Intestine, Small
Kaplan-Meier Estimate
Male
Middle Aged
Retrospective Studies
United States
/ epidemiology
Chemotherapy
Colorectal
GIST
Gastrointestinal stromal tumor
Imatinib
Small bowel
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
07
05
2019
accepted:
24
07
2019
pubmed:
8
8
2019
medline:
15
1
2021
entrez:
8
8
2019
Statut:
ppublish
Résumé
The aim of this study is to assess treatment trends and overall survival (OS) in small bowel (SB) and colorectal (CR) gastrointestinal stromal tumors (GIST) with respect to the introduction of imatinib in 2008. Patients diagnosed with SB and CR GIST were identified from the National Cancer Database (2004-2015). The primary outcome was 5- and 10-year OS. Patients were stratified by tumor site, time period (before and after imatinib), and treatment type. OS was analyzed using Kaplan-Meier survival curves, log-rank test, and Cox proportional hazards models. A total of 8441 cases were included (SB 81.66%; CR 18.34%). Radical resection was the most common treatment (SB 42.33%; CR 38.69%). The addition of chemotherapy to radical resection for SB GIST increased between the two time periods (31.76 to 40.43%; p < 0.001), and was associated with improved unadjusted and adjusted OS (2009-2015: adjusted HR [AHR] 0.73, 95% CI 0.59-0.89, p = 0.002). Patients with SB GIST had better 5- and 10-year OS compared with CR (SB 69.83% and 47.68%; CR 61.33% and 45.39%; p < 0.001), even after stratifying by treatment type and tumor size and adjusting for other factors (SB 5-year AHR 1.35, 95% CI 1.19-1.53; 10-year AHR 1.23, 95% CI 1.09-1.38; each p < 0.001). CR GIST are associated with lower OS than SB GIST. Radical resection is the most common treatment type for both sites. Chemotherapy with radical resection offers better OS in SB GIST, but not in CR GIST. Further studies are needed to assess the biology of CR GIST to explain the worse OS.
Sections du résumé
BACKGROUND
The aim of this study is to assess treatment trends and overall survival (OS) in small bowel (SB) and colorectal (CR) gastrointestinal stromal tumors (GIST) with respect to the introduction of imatinib in 2008.
METHODS
Patients diagnosed with SB and CR GIST were identified from the National Cancer Database (2004-2015). The primary outcome was 5- and 10-year OS. Patients were stratified by tumor site, time period (before and after imatinib), and treatment type. OS was analyzed using Kaplan-Meier survival curves, log-rank test, and Cox proportional hazards models.
RESULTS
A total of 8441 cases were included (SB 81.66%; CR 18.34%). Radical resection was the most common treatment (SB 42.33%; CR 38.69%). The addition of chemotherapy to radical resection for SB GIST increased between the two time periods (31.76 to 40.43%; p < 0.001), and was associated with improved unadjusted and adjusted OS (2009-2015: adjusted HR [AHR] 0.73, 95% CI 0.59-0.89, p = 0.002). Patients with SB GIST had better 5- and 10-year OS compared with CR (SB 69.83% and 47.68%; CR 61.33% and 45.39%; p < 0.001), even after stratifying by treatment type and tumor size and adjusting for other factors (SB 5-year AHR 1.35, 95% CI 1.19-1.53; 10-year AHR 1.23, 95% CI 1.09-1.38; each p < 0.001).
CONCLUSION
CR GIST are associated with lower OS than SB GIST. Radical resection is the most common treatment type for both sites. Chemotherapy with radical resection offers better OS in SB GIST, but not in CR GIST. Further studies are needed to assess the biology of CR GIST to explain the worse OS.
Identifiants
pubmed: 31388887
doi: 10.1007/s11605-019-04344-4
pii: 10.1007/s11605-019-04344-4
doi:
Substances chimiques
Antineoplastic Agents
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98-108Références
Oncology (Williston Park). 2009 Jan;23(1):54-61
pubmed: 19283922
Oncotarget. 2016 Jun 28;7(26):40735-40745
pubmed: 27166191
Ann Surg Oncol. 2012 Oct;19(11):3351-60
pubmed: 22878613
Annu Rev Med. 2012;63:247-58
pubmed: 22017446
Ann Surg Oncol. 2012 Oct;19(11):3361-7
pubmed: 22843188
Ann Surg. 2013 Sep;258(3):422-9
pubmed: 23860199
J Surg Oncol. 2008 Sep 1;98(3):175-8
pubmed: 18618605
Lancet Oncol. 2012 Mar;13(3):265-74
pubmed: 22153892
Surgery. 2003 Oct;134(4):656-65; discussion 665-6
pubmed: 14605627
Am J Surg Pathol. 2004 Jul;28(7):889-94
pubmed: 15223958
J Natl Compr Canc Netw. 2010 Apr;8 Suppl 2:S1-41; quiz S42-4
pubmed: 20457867
Br J Surg. 2015 Jul;102(8):965-71
pubmed: 25970743
Int J Colorectal Dis. 1989;4(2):91-6
pubmed: 2746135
Arch Pathol Lab Med. 2010 Feb;134(2):165-70
pubmed: 20121601
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):298-302
pubmed: 25277795
Dis Colon Rectum. 2006 May;49(5):609-15
pubmed: 16552495
Am J Gastroenterol. 2005 May;100(5):1002-8
pubmed: 15842570
Eur J Surg Oncol. 2014 Oct;40(10):1369-75
pubmed: 24994075
Ann Surg Oncol. 2017 Dec;24(13):3972-3980
pubmed: 29058144
JAMA. 2012 Mar 28;307(12):1265-72
pubmed: 22453568
J Surg Oncol. 2008 Oct 1;98(5):384-92
pubmed: 18668671
Am J Clin Oncol. 2011 Jun;34(3):314-6
pubmed: 20622646
JAMA Oncol. 2018 Dec 1;4(12):e184060
pubmed: 30383140
J Clin Oncol. 2003 Dec 1;21(23):4342-9
pubmed: 14645423
Am J Surg Pathol. 2006 Apr;30(4):477-89
pubmed: 16625094
J Surg Oncol. 2014 Jun;109(7):708-13
pubmed: 24510506
Scand J Gastroenterol. 2007 Oct;42(10):1221-9
pubmed: 17852882
J Clin Oncol. 2008 Feb 1;26(4):620-5
pubmed: 18235121
Ann Surg Oncol. 2013 Sep;20(9):2937-43
pubmed: 23760587
Ann Surg Oncol. 2014 Oct;21(11):3429-38
pubmed: 24854490
Virchows Arch. 2001 Jan;438(1):1-12
pubmed: 11213830
Cancer Epidemiol. 2016 Feb;40:39-46
pubmed: 26618334
J Clin Oncol. 2014 May 20;32(15):1563-70
pubmed: 24638003
J Cancer Res Clin Oncol. 2017 Apr;143(4):727-734
pubmed: 28083710
Ann R Coll Surg Engl. 2015 Apr;97(3):215-20
pubmed: 26263807
Hum Pathol. 2002 May;33(5):459-65
pubmed: 12094370
Ann Surg. 2000 Jan;231(1):51-8
pubmed: 10636102
Nat Rev Gastroenterol Hepatol. 2009 Jun;6(6):363-71
pubmed: 19365407
Ann Surg Oncol. 2010 Jan;17(1):109-14
pubmed: 19841981
Lancet. 2009 Mar 28;373(9669):1097-104
pubmed: 19303137
J Clin Oncol. 2004 Sep 15;22(18):3813-25
pubmed: 15365079
Z Gastroenterol. 2008 Aug;46(8):760-5
pubmed: 18759198
AJR Am J Roentgenol. 2014 Nov;203(5):980-91
pubmed: 25341135
Cancer Biol Ther. 2004 Mar;3(3):251-8
pubmed: 14726714
Ann Ital Chir. 2015 May-Jun;86(3):219-27
pubmed: 26098671
Surg Today. 2013 Oct;43(10):1162-7
pubmed: 23143169
Am J Surg Pathol. 2005 Jan;29(1):52-68
pubmed: 15613856
Surgery. 2007 Jun;141(6):748-56
pubmed: 17560251
J Gastrointest Oncol. 2017 Jun;8(3):466-473
pubmed: 28736634
Ann Oncol. 2012 Oct;23 Suppl 7:vii49-55
pubmed: 22997454
Ann Surg Oncol. 2013 Feb;20(2):586-92
pubmed: 22965573